Newsroom
News & press releases.
Announcements, product updates and analysis from Paxton-Digital. For long-form briefs, see Editorial Insights.
Daniel Strickland Is the Voice the Room Has Been Waiting For
Singer, guitarist and pianist Daniel Strickland blends country heart, roadhouse rock and faith-rooted songwriting across four independent singles. Meet Paxton-Digital’s first featured artist, then play Fit the Room, the Daniel Strickland Live…
Press release · October 10, 2026Paxton-Digital Puts Prognosis at the Center of Paxton Scout: IP, Market and Clinical Outlooks
Paxton Scout puts prognosis at its center — an IP and market outlook and a clinical outlook — plus a free patent term and exclusivity estimator.
Press release · September 30, 2026AI Infrastructure Is Becoming a Power-and-Token Business
The AI infrastructure race is moving beyond GPUs. Power, cooling, optics, regional factories, and contracted inference capacity are becoming the real operating system of the next cycle.
News · November 14, 2026Japan’s Emergency Cybersecurity Package: AI Defenders, Rescue Teams and the Race Against Faster Attacks
After a wave of data breaches at major companies and agencies, Japan announced a 10 billion yen package built around AI tools, cyber rescue teams and preemptive defense. Here is what it…
News · November 13, 2026Moderna’s $1.3 Billion Patent Appeal: Why Section 1498 Matters to Every Government Contractor
The Federal Circuit heard arguments on whether Moderna's COVID-19 vaccine doses were made for the government, a question that will decide up to $1.3 billion in patent payments and reshape contractor IP…
Healthcare M&A · November 12, 2026Vantive Sells Most of Its Hemodialysis Business to Rockwell Medical: A Carve-Out Playbook for Health Care Leaders
Vantive agreed to divest most of its hemodialysis business, including an Italian plant, to Rockwell Medical while keeping its Theranova dialyzers. Here is what the carve-out shows about portfolio focus and continuity…
Healthcare M&A · November 11, 2026Oura’s $625 Million Counsel Health Deal: Why a Smart-Ring Maker Is Buying a Care Platform
Oura agreed to buy AI-native primary care startup Counsel Health for $625 million. Here is what the deal says about wearables, AI and clinical care.
Healthcare M&A · November 10, 2026AstraZeneca’s Reported $10 Billion Offer for Rhythm: What a Rare-Obesity Deal Says About Pharma’s Next Bets
AstraZeneca made a non-binding offer worth about $10 billion for Rhythm Pharmaceuticals, Reuters reported, a move that would give it an entry into obesity through rare disease. Here is what the reported…
Healthcare M&A · November 9, 2026CVS Health Plans to Split Off Its Pharmacy Chain: What Unwinding Health Care’s Biggest Vertical Bet Means for Dealmakers
CVS Health will separate its roughly 9,000-store pharmacy business from Aetna, Caremark and its care delivery units by the first half of 2028. Paxton-Digital breaks down the structure, the numbers, the regulatory…
Healthcare M&A · November 8, 2026Cinven’s $2.6 Billion Theramex Deal: Why Private Equity Is Betting on Women’s Health and In-Licensing
Cinven has agreed to buy London-based Theramex from Carlyle and PAI Partners. The deal highlights two themes executives should track: women's health as an underserved growth market and the value of an…
Healthcare M&A · November 7, 2026Integris Health Joins Kaiser-Founded Risant: Inside the Platform Model Reshaping Health System Deals
Oklahoma's Integris Health will become the third system in Risant Health, the nonprofit Kaiser Permanente created in 2023. Its CEO says it is not a traditional merger. Here is what the platform…
Healthcare M&A · November 6, 2026Bon Secours Mercy Health’s $5.7 Billion Bet on Surgery Centers: What the Surgery Partners Take-Private Signals
A nonprofit Catholic health system is taking one of the country's largest outpatient surgery operators private, with Bain Capital staying on as a major partner. The deal shows where hospital strategy and…
News · November 5, 2026Lonza to Buy Five Merck KGaA U.S. Plants in Push Into Antibody-Drug Conjugates
The Swiss contract manufacturer will add sites in Missouri, Wisconsin, California and Indiana, along with about 1,100 employees, in a deal expected to close in mid-2027.
News · November 4, 2026A $40 HIV Shot Behind a U.S. Patent Wall: What the Generic Lenacapavir Approval Teaches About IP Licensing
The FDA has tentatively approved a generic version of the twice-a-year HIV prevention shot for 120 lower-income countries at about $40 a year, while the patented U.S. brand lists at $28,218. Here…
Healthcare M&A · November 3, 2026Privia Pays About $36 Million for Cano Health’s Medicare ACO, Adding 36,000 Lives for 2027
Privia Health bought Cano Health's American Choice Healthcare ACO for about $36 million in cash, adding 36,000-plus Medicare lives starting Jan. 1, 2027.
Healthcare M&A · November 2, 2026Karyopharm Files for Chapter 11 to Sell Itself, With Gamida Cell Parent Ayrmid as Lead Bidder
Cancer drugmaker Karyopharm Therapeutics filed for bankruptcy to run a court-supervised sale, with Ayrmid leading the bidding for the company and its drug Xpovio.
Healthcare M&A · November 1, 2026Private Equity’s Hospital Count Jumps to 561 as Massachusetts Reviews Select Medical’s Buyout After the Fact
A tracker counts 561 private equity-owned U.S. hospitals, up 114 since July, while Massachusetts reviews Select Medical's buyout months after it closed.
Healthcare M&A · October 31, 2026Viatris Opens Its $36.50-a-Share Tender for Pacira, Setting a Nov. 16 Deadline for the Non-Opioid Pain Deal
Viatris launched its cash tender for Pacira BioSciences, maker of Exparel and Zilretta. The terms, the deadline and what the $1.65 billion deal signals.
News · October 30, 2026Open Enrollment 2027: Compare Two Health Plans on Total Yearly Cost
HealthCare.gov enrollment runs Nov. 1 to Jan. 15 and Massachusetts to Jan. 23. How to compare two plans on premiums, deductibles and the yearly cap.
News · October 29, 2026Two $150 Million Biotech IPOs, One From Boston, Test the Fall Window
Parkinson's cell-therapy developer Aspen Neuroscience and Boston's Bambusa Therapeutics each seek about $150 million in Nasdaq IPOs this week.
Healthcare M&A · October 28, 2026Bon Secours Affiliate Agrees to Take Surgery Partners Private in $5.7 Billion Deal
HealthSpan Partners, a Bon Secours Mercy Health affiliate, will pay $23.50 a share for Surgery Partners as Bain Capital rolls its 39% stake.
News organisation · October 27, 202656 Hospital Deals and Counting: 2026 Has Already Passed All of Last Year
Kaufman Hall tallied 16 announced hospital deals in Q3 and 56 through September, topping 2025’s 15-year low of 46. Mega-mergers and joint ventures are driving it.
News · October 26, 2026Lycia’s $318 Million IPO Pops in Its Debut, Testing Wall Street’s Appetite for Protein Degraders
Lycia Therapeutics sold 17.6 million shares at $18, the top of its range, then jumped in its Nasdaq debut. What LYCA says about the 2026 IPO window.
Healthcare M&A · October 25, 2026Gilead Pays Up to $1.9 Billion for Vir’s T-Cell Engagers as Pharma Keeps Buying Oncology Pipelines
The license covers three solid-tumor programs with $90 million upfront. Agilent, Galderma and BlackRock's HPS also closed notable deals in a week with no new IPOs.
Healthcare M&A · October 24, 2026Rush and Endeavor Plan a 12-Hospital, $11 Billion Chicago System, Targeting an Early-2027 Close
The merger would pair Rush University System for Health's academic medicine with Endeavor Health's suburban footprint. It is the largest hospital combination announced this month.
News organisation · October 23, 2026Kaiser Permanente’s Risant Health Moves Into Oklahoma With a Deal for INTEGRIS Health
Oklahoma’s largest nonprofit system, with 20 hospitals and about 13,000 employees, would become Risant’s third system after Geisinger and Cone Health.
News · October 22, 2026Alcon Pays $550 Million for Neurotech and Its Approved Eye Cell Therapy
Alcon bought Neurotech for $550 million upfront plus milestones, adding Encelto, the only FDA-approved MacTel therapy. The terms, risks and signals.
News · October 21, 2026Abbott Plans to Spin Off Its $8.5 Billion Nutrition Business
Abbott said it will separate its global nutrition unit, home to Similac, Pedialyte and Ensure, into an independent public company, with completion expected at the end of 2027.
Healthcare M&A · October 20, 2026Roche Returns to Hansoh With ADC Partnership Valued at More Than $15 Billion
Earlier this week Roche agreed to pay Hansoh Pharma $400 million upfront plus $110 million after one year in a broad antibody-drug conjugate collaboration with potential value above $15 billion.
Healthcare M&A · October 19, 2026Merck KGaA to Buy Silence Therapeutics for $20 a Share, Betting on RNAi Drug for Polycythemia Vera
Germany's Merck KGaA agreed to acquire Silence Therapeutics in a $1.3 billion cash deal that values its U.S.-listed shares at a 130% premium.
Healthcare M&A · October 18, 2026AstraZeneca Signs Up to $1.5 Billion AI Target-Discovery Deal With insitro in MASH and Cardiomyopathy
Earlier this week AstraZeneca agreed to pay insitro $40 million upfront to use its Virtual Human AI platform to find new drug targets in MASH and cardiomyopathies.
News · October 17, 2026Labcorp to Buy BioReference Testing Businesses From Opko for Up to $872 Million
Earlier this week Labcorp agreed to acquire select BioReference Health testing businesses, including the 4Kscore prostate cancer test, for $722 million upfront plus up to $150 million in contingent payments.
News organisation · October 16, 2026Iambic’s $150M IPO Tests Appetite for AI-Built Cancer Drugs
Iambic Therapeutics priced its IPO at $16, raising $150 million, then closed up about 18% on debut. What the AI drug developer's valuation says about the field.
News organisation · October 15, 2026Rush and Endeavor Build a Nearly $11 Billion System on Razor-Thin Margins
Rush University System for Health and Endeavor Health plan to merge into a 12-hospital, nearly $11 billion academic system under the Rush name. Both run on margins near 1%. Paxton-Digital breaks down…
News organisation · October 14, 2026Two Biotechs, One Window: Iambic and Cambridge’s City Therapeutics Test the Fall IPO Market
AI drug designer Iambic and Cambridge RNAi developer City Therapeutics are seeking about $325 million combined at their midpoints on Nasdaq this week. The terms, the pipelines, what is confirmed, and what…
News organisation · October 13, 2026STERIS Pays $2.1 Billion to Make Surgery Safer, and Bets Big on the Operating Room’s Consumables
STERIS will pay $2.1 billion (about $1.8 billion net of tax benefits) for Xodus Medical, maker of the Pink Pad surgical positioning system, a roughly 55%-margin consumables business. Paxton-Digital breaks down the…
News organisation · October 12, 2026A $5.8 Billion Signal: Healthcare’s Deal Machine Is Moving Care Into the Home
CD&R and McKesson agree to take Option Care Health private in a $5.8 billion deal, as billions more flow into rare disease, radiopharma and telehealth and Oura shelves its IPO. What it…
News · October 9, 2026TRexBio and Retension Raise a Combined $161.7 Million in IPOs as Biotech Listings Reach 29 for the Year
TRexBio priced its IPO at $14, the low end of its range, and Retension priced at the $12 midpoint, with both set to begin trading on Oct. 9.
News · October 8, 2026Viatris to Acquire Pacira for $36.50 a Share to Build a Non-Opioid Pain Business
Viatris agreed to buy Pacira BioSciences, maker of Exparel and Zilretta, in a cash deal BioSpace valued at $1.65 billion, with closing expected by the end of 2026.
News · October 7, 2026Matchpoint Therapeutics Raises $150 Million Series B to Bring Oral T Cell Modulator Into the Clinic
Watertown, Massachusetts-based Matchpoint raised a $150 million Series B co-led by Nextech Invest and Norwest to advance MPT-062, an oral drug for autoimmune disease.
Healthcare M&A · October 6, 2026GE HealthCare to Acquire Sofie Biosciences for $945 Million to Secure PET Tracer Manufacturing
Earlier this week GE HealthCare agreed to buy Sofie Biosciences, a contract manufacturer of PET radiopharmaceuticals with 15 U.S. sites, for $945 million in cash.
Healthcare M&A · October 5, 2026Shionogi to Buy IntraBio for $2 Billion, Adding Rare Disease Drug Aqneursa
Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion in cash, gaining Aqneursa, approved for Niemann-Pick disease type C and Ataxia-Telangiectasia.
News · October 4, 2026Orlando Health Completes RMC Acquisition, Renaming Anniston Hospital Baptist Health Calhoun
Earlier this week Orlando Health finalized its acquisition of RMC Health System in Anniston, Alabama, a 375-bed system that now operates as Baptist Health Calhoun Hospital.
Healthcare M&A · October 3, 2026Varda Raises $251 Million at a $1.6 Billion Valuation to Scale Drug Manufacturing in Orbit
Earlier this week Varda Space Industries closed a $251 million Series D co-led by Lux Capital and Natural Capital to expand missions that process pharmaceuticals in microgravity.
Healthcare M&A · October 2, 2026Novartis Licenses Abogen’s mRNA-Encoded T Cell Engager in Deal Worth Up to $7.8 Billion
Novartis will pay China's Abogen $575 million upfront for rights to ABO2203 and an option on further programs from its RNA platform.
News · October 1, 2026Sanofi Pays Regeneron $1 Billion Upfront to Expand Alliance in Search of Dupixent’s Successors
Sanofi and Regeneron broadened their long-running partnership to co-develop four long-acting antibodies, with Regeneron receiving $1 billion upfront and up to $7 billion in milestones.
News · September 29, 2026HealthPartners and Essentia Health Plan to Combine Into a 22-Hospital Upper Midwest System
Minnesota nonprofits HealthPartners and Essentia Health announced plans to merge, creating a system with 22 hospitals and about 45,000 employees under the HealthPartners name.
Healthcare M&A · September 28, 2026Merck Pays $400 Million Upfront for SciBrunch’s KRAS G12D Molecular Glue in Deal Worth Up to $2.13 Billion
Merck licensed exclusive global rights to SPR2015, a preclinical oral KRAS G12D inhibitor from China-based SciBrunch, as it diversifies ahead of Keytruda's patent expiration.
News · September 27, 2026Roche Signs Up to $2 Billion Deal With Atavistik for Allosteric Cardiometabolic Drugs
Earlier this week Roche agreed to pay Atavistik Bio $70 million upfront to discover drugs for cardiovascular, renal and metabolic targets using its allosteric platform.
Healthcare M&A · September 26, 2026Genentech Partners With AI Antibody Firm Earendil on Cancer Bispecifics in Deal Worth Over $1.5 Billion
Earlier this week Genentech agreed to pay Earendil Labs $55 million upfront to develop bispecific antibody cancer therapies, with total potential value above $1.5 billion.
News · September 25, 2026ADARx Debuts After Upsized $446 Million IPO, the Third-Largest Biotech Listing of 2026
RNA medicines developer ADARx Pharmaceuticals sold 26.25 million shares at $17, the top of its range, and AbbVie bought a stake in a concurrent private placement.
Healthcare M&A · September 24, 2026Lilly Pays InnoCare $100 Million Upfront in Discovery Pact Worth Up to About $3.25 Billion in Milestones
Eli Lilly agreed to work with Beijing-based InnoCare Pharma on drug candidates for up to five undisclosed targets, adding to a year of heavy dealmaking.
Healthcare M&A · September 23, 2026Enveda Raises $311 Million Series E to Push Oral Obesity and Inflammation Drugs Into Later Trials
AI-driven drug discovery company Enveda closed a $311 million Series E crossover round led by Catalio Capital, bringing total funding to more than $845 million.
Healthcare M&A · September 22, 2026Boehringer Ingelheim Bets Up to More Than $1 Billion on Envisagenics’ AI Splicing Platform for Solid Tumors
Boehringer Ingelheim partnered with New York-based Envisagenics to find cancer-specific RNA splicing targets, in a deal that could exceed $1 billion including milestones.
Healthcare M&A · September 21, 2026Telix to Acquire Germany’s ITM for $1.65 Billion Upfront in Radiopharmaceutical Consolidation
Australia's Telix agreed to buy Isotope Technologies Munich for $1.65 billion upfront plus up to $700 million in contingent payments, combining diagnostics, isotope supply and the ITM-11 therapy.
Healthcare M&A · September 20, 2026Innate Pharma and Sobi Lacutamab Partnership Takes Effect, Triggering $75 Million Upfront
Earlier this week Innate Pharma said its licensing partnership with Sobi for T-cell lymphoma drug lacutamab became effective, triggering a $75 million upfront payment.
News · September 19, 2026LEO Pharma Closes Dersimelagon Deal as FDA Grants Priority Review for Rare Skin Disease Drug
Earlier this week LEO Pharma completed its acquisition of worldwide rights to dersimelagon from Tanabe Pharma and said the FDA accepted the drug's application with priority review.
Healthcare M&A · September 18, 2026Electra Therapeutics Raises $350 Million in Upsized IPO, Then Slips in Nasdaq Debut
Immunology and cancer biotech Electra Therapeutics sold 23.3 million shares at $15, the midpoint of its range, and began trading under ETRA on Sept. 18.
News · September 17, 2026Novo Nordisk Teams With Orbis Medicines on Oral Macrocycles in Deal Worth Up to $1.4 Billion
Novo Nordisk agreed to work with Danish startup Orbis Medicines to discover macrocyclic drugs for cardiometabolic targets, with Orbis eligible for up to $1.4 billion plus royalties.
Healthcare M&A · September 16, 2026J&J Sells Laminar Heart Device Assets It Bought for $400 Million Less Than Three Years Ago
Johnson & Johnson is selling key assets of Laminar, a left atrial appendage closure developer it acquired in 2023, to Jaguar LAA, a new company backed by Santé Ventures.
Put it to work.
Scout and the connected tools are included with SCOUT Pro, an eligible Paxton-Digital plan. Projects and custom builds start with a conversation.